Pacific Biosciences of California PACB Instrument revenue — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacific Biosciences of California's instrument revenue — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Pacific Biosciences of California's instrument revenue — total revenue?
- Pacific Biosciences of California (PACB) reported instrument revenue — total revenue of $9.72M in Q1 2026.
- How has Pacific Biosciences of California's instrument revenue — total revenue changed year-over-year?
- Pacific Biosciences of California's instrument revenue — total revenue decreased by 11.8% year-over-year, from $11.02M to $9.72M.
- What is the long-term trend for Pacific Biosciences of California's instrument revenue — total revenue?
- Over 4 years (2021 to 2025), Pacific Biosciences of California's instrument revenue — total revenue has grown at a -3.2% compound annual growth rate (CAGR), from $61.32M to $53.82M.
- What does instrument revenue — total revenue mean?
- This metric represents the total revenue generated from the sale of genetic sequencing hardware platforms and associated instrumentation systems. It serves as a primary indicator of market adoption for the company's core technology and reflects the initial capital investment made by customers to access the platform. Growth in this segment is critical for expanding the installed base, which subsequently drives long-term recurring revenue through consumables and service contracts.